Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide DDI with Metformin and Digoxin
NCT02249910Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2014
- Primary completion
- Mar 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the metformin plasma concentration-time curve and Area under the digoxin plasma concentration-time curve. Started Sep 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02249910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249910.